Drug intelligence / Profile preview

IMU-381

Development stage: Preclinical
Lead developer: Immunic
Modality: Small Molecules

Overview

IMU-381 is a next-generation small molecule drug candidate developed by Immunic to address gastrointestinal diseases. It is designed with improved overall properties compared to earlier compounds and is currently in preclinical development. The specific mechanism of action for IMU-381 has not been publicly disclosed, but it is part of Immunic's pipeline focused on chronic inflammatory and autoimmune conditions affecting the digestive system.

Beyond the preview

Go deeper on IMU-381.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMU-381.

Explore the full profile